| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Arnaud Jacquel | Q39868748 |
| Patrick Auberger | Q56997684 | ||
| P2093 | author name string | Guillaume Robert | |
| Maeva Dufies | |||
| Ophelie Cassuto | |||
| P2860 | cites work | AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance | Q24648017 |
| Ponatinib in refractory Philadelphia chromosome-positive leukemias | Q27851967 | ||
| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia | Q34620246 | ||
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia | Q36047171 | ||
| Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells | Q39512409 | ||
| Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. | Q39628692 | ||
| P433 | issue | 11 | |
| P921 | main subject | leukemia | Q29496 |
| imatinib | Q177094 | ||
| P1104 | number of pages | 2 | |
| P304 | page(s) | 1645-1646 | |
| P577 | publication date | 2013-05-10 | |
| P1433 | published in | Cell Cycle | Q1254166 |
| P1476 | title | Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines | |
| P478 | volume | 12 |
| Q39106999 | Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. |
| Q39062384 | Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity |
| Q34781322 | Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia |
| Q33576849 | Latest progress in tyrosine kinase inhibitors |
Search more.